Estimating required information size by quantifying diversity in random-effects model meta-analyses
- PMID: 20042080
- PMCID: PMC2809074
- DOI: 10.1186/1471-2288-9-86
Estimating required information size by quantifying diversity in random-effects model meta-analyses
Abstract
Background: There is increasing awareness that meta-analyses require a sufficiently large information size to detect or reject an anticipated intervention effect. The required information size in a meta-analysis may be calculated from an anticipated a priori intervention effect or from an intervention effect suggested by trials with low-risk of bias.
Methods: Information size calculations need to consider the total model variance in a meta-analysis to control type I and type II errors. Here, we derive an adjusting factor for the required information size under any random-effects model meta-analysis.
Results: We devise a measure of diversity (D2) in a meta-analysis, which is the relative variance reduction when the meta-analysis model is changed from a random-effects into a fixed-effect model. D2 is the percentage that the between-trial variability constitutes of the sum of the between-trial variability and a sampling error estimate considering the required information size. D2 is different from the intuitively obvious adjusting factor based on the common quantification of heterogeneity, the inconsistency (I2), which may underestimate the required information size. Thus, D2 and I2 are compared and interpreted using several simulations and clinical examples. In addition we show mathematically that diversity is equal to or greater than inconsistency, that is D2 >or= I2, for all meta-analyses.
Conclusion: We conclude that D2 seems a better alternative than I2 to consider model variation in any random-effects meta-analysis despite the choice of the between trial variance estimator that constitutes the model. Furthermore, D2 can readily adjust the required information size in any random-effects model meta-analysis.
Figures



Similar articles
-
Trial Sequential Analysis in systematic reviews with meta-analysis.BMC Med Res Methodol. 2017 Mar 6;17(1):39. doi: 10.1186/s12874-017-0315-7. BMC Med Res Methodol. 2017. PMID: 28264661 Free PMC article.
-
Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses.Int J Epidemiol. 2009 Feb;38(1):287-98. doi: 10.1093/ije/dyn188. Epub 2008 Sep 29. Int J Epidemiol. 2009. PMID: 18824466
-
Quantifying heterogeneity in a meta-analysis.Stat Med. 2002 Jun 15;21(11):1539-58. doi: 10.1002/sim.1186. Stat Med. 2002. PMID: 12111919
-
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.Health Technol Assess. 2001;5(33):1-56. doi: 10.3310/hta5330. Health Technol Assess. 2001. PMID: 11701102 Review.
-
Apparently conclusive meta-analyses on interventions in critical care may be inconclusive-a meta-epidemiological study.J Clin Epidemiol. 2019 Oct;114:1-10. doi: 10.1016/j.jclinepi.2019.05.011. Epub 2019 Jun 11. J Clin Epidemiol. 2019. PMID: 31200004 Review.
Cited by
-
Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews.Cochrane Database Syst Rev. 2016 Mar 18;3(3):ED000111. doi: 10.1002/14651858.ED000111. Cochrane Database Syst Rev. 2016. PMID: 27030037 Free PMC article. No abstract available.
-
Interventions for treating intrahepatic cholestasis in people with sickle cell disease.Cochrane Database Syst Rev. 2020 Jun 22;6(6):CD010985. doi: 10.1002/14651858.CD010985.pub4. Cochrane Database Syst Rev. 2020. PMID: 32567054 Free PMC article.
-
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).PLoS One. 2021 Mar 11;16(3):e0248132. doi: 10.1371/journal.pone.0248132. eCollection 2021. PLoS One. 2021. PMID: 33705495 Free PMC article.
-
Adding exercise to usual care in patients with hypertension, type 2 diabetes mellitus and/or cardiovascular disease: a protocol for a systematic review with meta-analysis and trial sequential analysis.Syst Rev. 2019 Dec 17;8(1):330. doi: 10.1186/s13643-019-1233-z. Syst Rev. 2019. PMID: 31847918 Free PMC article.
-
Modified Buzhong Yiqi decoction for myasthenia gravis: A systematic review protocol.Medicine (Baltimore). 2018 Dec;97(50):e13677. doi: 10.1097/MD.0000000000013677. Medicine (Baltimore). 2018. PMID: 30558075 Free PMC article.
References
-
- Devereaux PJ, Beattie WS, Choi PT, Badner NH, Guyatt GH, Villar JC. How strong is the evidence for the use of perioperative beta-blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ. 2005;331(7512):313–21. doi: 10.1136/bmj.38503.623646.8F. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical